Compare Cassava Sciences Inc (FLNA) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vertiv Holdings Co — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Vertiv Holdings Co trades at $292.27 (market cap $116.99B). The key difference: Vertiv Holdings Co is far larger — about 2201.5× Cassava Sciences Inc's market cap, and Vertiv Holdings Co pays a 0.08% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | VRT | |
|---|---|---|
Market Cap | $53.14M | $116.99B |
Sector | Health | Technology |
52-Week High | $4.64 | $376.23 |
52-Week Low | $1.09 | $121.82 |
Enterprise Value | -$33.43M | $117.75B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Vertiv Holdings Co. (VRT) trades at $289.06, down 4.78% over the past 24 hours, with technical indicators signaling a bearish short-term trend. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.17 surpassing the $1.00 estimate. Revenue reached $10.23 billion in 2025, with net income of $1.33 billion, while analyst consensus remains overwhelmingly bullish with a $404.33 price target. Recent news highlights Vertiv's exposure to AI data center infrastructure growth, including a $15 billion order backlog.
The outlook for VRT is positive due to robust AI-driven demand for data center power and cooling solutions, supported by a high analyst buy rating of 94.74%. Key risks include elevated valuation multiples (P/E of 76.53) and competitive pressures in the infrastructure sector. Investors should monitor execution on the large backlog and Q2 2026 earnings release on July 29, 2026, for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
